ROCK2 agent stops GVHD

ROCK2 agent stops GVHD

    Nature Biotechnology

    volume39, page 1323(2021) Cite this short article

    ROCK2 (rho-associated coiled-coil-containing protein kinase-2) is a protein with numerous functions, and its activity is upregulated in severe inflammatory injury and persistent illness such as diabetes, metabolic syndrome and idiopathic lung fibrosis. Obstructing ROCK2 acts by stopping pro-inflammatory T H17 cells and enhancing regulative T cells to bring back homeostasis. In September the FDA authorized Jakafi (ruxolitinib) for persistent GVHD after failure of a couple of lines of systemic treatment.

    Access choices

    Subscribe to Journal

    Get complete journal gain access to for 1 year

    99,00 EUR

    just 8,25 EUR per problem

    Tax estimation will be settled throughout checkout.

    Rent or Buy short article

    Get time restricted or complete post gain access to on ReadCube.

    from$ 8.99

    All rates are NET rates.

    About this post

    Read More

    Author: admin

    Leave a Reply

    Your email address will not be published. Required fields are marked *